By Ryan Ridge, Senior Director, IRT Operations, YPrime
Ongoing patient recruitment and retention challenges were intensified by the Covid-19 global pandemic. Adoption of alternative trial designs and technology solutions accelerated among clinical research professionals looking for ways to make it easier for patients to participate in clinical trials, regardless of their location. One alternative trial design is the Direct-to-Patient (DtP) strategy, where study drug is shipped directly to the patient, and technology solutions play a critical role in managing the supply chain and ensuring that, at the end of the lifecycle, there is full accountability. This article explores what DtP is, as well as its benefits and complexities.